Retatrutide is one of the most closely watched investigational medications in metabolic health. It is currently in clinical trials and is not FDA-approved and not available to prescribe. Here's an honest look at what it is and where it stands, so you can follow the science with us.
Retatrutide is an investigational triple-agonist — it targets three receptors involved in metabolism (GLP-1, GIP, and glucagon), where current medications like semaglutide target one and tirzepatide target two. In published Phase 2 research it has drawn significant attention in the medical and metabolic-health community. It is sometimes informally called a "GLP-3," though that term isn't technically accurate.
Because it is still being studied, no licensed provider or pharmacy can legally prescribe or compound it today. Any source claiming to sell "retatrutide" now is operating outside the law — a real safety risk we'd urge you to avoid.
The stages below reflect the general FDA drug-approval pathway and widely reported industry expectations — not a Vincera timeline or a promise of availability. Dates are estimates that can and do change.
Join our research-updates list and we'll send accurate, hype-free updates on retatrutide and other emerging treatments as they move through the approval process. No promises of availability — just the facts as they develop.
Important: This page is for general educational purposes only and is not medical advice, a recommendation, or an offer to sell any product. Retatrutide is investigational and not approved by the U.S. Food and Drug Administration. Statements about trial stages and timing reflect publicly reported information and general industry expectations, which may change. Vincera Health does not offer, sell, or maintain a waitlist to purchase retatrutide.